| The K-Ras(V14I) activating protein is able to induce cancer, although at a much lower level than the classical K-Ras(G12V) oncogene, and that it can be significantly modulated by both genetic and non-genetic events. | None |
| our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression. | None |
| Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors. | None |
| we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca(2+)-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. | None |
| The current study uncovers the contribution of oncogenic KRAS to serum marker CA125 production through a mechanism that involves the ERK/c-Myc axis. | None |
| Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types. | None |
| Sequencing of over 11,000 advanced human cancers revealed mutant allele imbalance in 55% of 1,168 KRAS mutant tumors of all histologic types, many of which lost WT KRAS through diverse genetic mechanisms. Clonal evolution at the KRAS locus resulting in increased oncogene expression and loss of the normal allele may identify a subset of cancers with increased dependence on MAPK signaling in some tissue contexts. | None |
| A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. | None |
| analysis of the G-quadruplex involved in transcriptional regulation of the KRAS proto-oncogene promoter | None |
| Accelerated malignant conversion of human HBL-100 cells by the v-Ki-ras oncogene. | None |
| our study indicated that PKC alpha and beta appeared coping with oncogenic Ras or mutated Akt to maintain the balance of the homeostasis in cancer cells. Once these PKC isoforms were suppressed, the redox state in the cancer cells was disrupted, which elicited persistent oncogenic stress and subsequent apoptotic crisis. | None |
| Cloning of bovine GAP and its interaction with oncogenic ras p21. | None |
| we demonstrate that oncogenic p110alphaH1047R, K-RasG12V, H-RasG12V, and Her2 use a common Akt1-FOXO3a pathway in suppression of DeltaNp63alpha expression and, consequently, promote cell migration/invasion and tumor metastasis. Thus, DeltaNp63alpha may function as a critical integrator of oncogenic signals in cell motility and cancer metastasis. | None |
| These results delineate the signaling cascades connecting oncogenic K-Ras(V12) with alpha6- and alphaV-integrin functions to modulate cancer cell survival and tumorigenesis, and reveal new possible strategies to target highly oncogenic K-Ras(V12) mutants. | None |
| The structure model of the CaM-K-Ras4B HVR association provides plausible clues to CaM_s regulatory action in PI3Kalpha activation involving the ternary complex in cell proliferation signaling by oncogenic K-Ras4B. | None |
| The defined role of oncogenic KRAS in the regulation of altered metabolic signaling pathways in KRAS-driven cancers.[review] | None |
| MALAT1 acts as a tumour promoter at least in part by binding miR-217 and sequestering the molecule in the nucleus, thereby promoting oncogenic KRAS expression in PDAC. | None |
| this study identified a novel mechanism by which oncogenic RAS promotes survival of malignant intestinal epithelial cells. This mechanism is driven by RAS-dependent loss of ATG12 in these cells. | None |
| The role of KRAS oncogenic signaling in cancer cells.[review] | None |
| LSD1 and JMJD2C disable oncogenic Ras- or Braf-induced senescence by enabling the expression of E2F target genes | None |